Table 3.
A comparison of patient reported outcomes over time by group. (AE: adverse event, IQR: interquartile range, WPAI: Work Productivity and Activity Impairment, EQ5D: EuroQol-5D-3 L, WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index, SAPS: Self-Administered Patient Satisfaction scale)
| Pre-op Median (IQR) |
3 Months Median (IQR) |
6 Months Median (IQR) |
9 Months Median (IQR) |
12 Months Median (IQR) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| n | n | n | n | n | |||||||
| WPAI | |||||||||||
| No AE | 70 (50,80) | 106 | 20 (10,30) | 76 | 10 (0,20) | 71 | 0 (0,20) | 68 | 0 (0,20) | 72 | |
| Reported | 70 (70,90) | 6 | 25 (10,30) | 6 | 0 (0,10) | 3 | 0 (0,50) | 3 | 0 (0,20) | 3 | |
| Confirmed | 65 (40,80) | 4 | 30 (20,40) | 4 | 20 (0,20) | 3 | 20 5,30) | 4 | 15 (5,25) | 4 | |
| EQ5D | |||||||||||
| No AE | 0.52 (0.6, 0.69) | 395 | 0.76 (0.62, 1) | 313 | 0.8 (0.69, 1) | 298 | 0.81 (0.69, | 285 | 0.88 (0.71, 1) | 289 | |
| Reported | 0.52 (0.16, 0.59) | 18 | 0.62 (0.52, 0.76) | 17 | 0.7 (0.55, 0.91) | 16 | 0.7 (0.62, 0.78) | 14 | 0.7 (0.52, 0.82) | 14 | |
| Confirmed | 0.16 (0.02, 0.69) | 15 | 0.59 (0.36,0.76) | 15 | 0.75 (0.64, 1) | 12 | 0.7 (0.22, 0.91) | 12 | 0.76 (0.71, 1) | 13 | |
| WOMAC | |||||||||||
| No AE | 59.9 (50, 69.8) | 364 | 16.7 (8.3, 31.2) | 269 | 12.5 (4.4, 27.1) | 267 | 10.4 (3.1, 23) | 256 | 7.3 (2.1, 16.8) | 256 | |
| Reported | 60.1 (54.2, 77.1) | 18 | 29.2 (15.2, 40.1) | 16 | 22.9 (8.3, 50) | 17 | 26 (12.5, 40.1) | 16 | 22.4 (7.3, 46.9) | 14 | |
| Confirmed | 59.4 (55.2, 70.8) | 15 | 25.9 (15.6, 51) | 15 | 21.7 5.2, 33.3) | 11 | 26.5 (6.5, 29.9) | 12 | 15.6 (5.2, 29.1) | 13 | |
| SAPS | |||||||||||
| No AE | 93.8 (81.3, 100) | 268 | 100 (81.3, 100) | 250 | 100 (81.3, 100) | 247 | 100 (87.5, 100) | 248 | |||
| Reported | 78.1 (75, 100) | 18 | 87.5 (68.8, 100) | 17 | 93.8 (75, 100) | 15 | 87.5 (75, 100) | 14 | |||
| Confirmed | 81.3 (68.8, 100) | 13 | 81.3 (71.9, 100) | 12 | 87.5 (62.5, 100) | 12 | 81.3 (62.5, 100) | 11 | |||